Search

Your search keyword '"Mistry, Haleigh"' showing total 28 results
Start Over Author "Mistry, Haleigh"
28 results on '"Mistry, Haleigh"'

1. Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy

Author

Strati, Paolo, Jallouk, Andrew P., Sun, Ryan, Choi, Jaihee, Das, Kaberi, Cherng, Hua-Jay, Ahmed, Sairah, Lee, Hun J., Iyer, Swaminathan P., Nair, Ranjit, Nastoupil, Loretta J., Steiner, Raphael E., Huff, Chad D., Yu, Yao, Mistry, Haleigh, Pulsifer, Brittany, Noorani, Mansoor, Saini, Neeraj, Shpall, Elizabeth J., Kebriaei, Partow, Flowers, Christopher R., Westin, Jason R., Hildebrandt, Michelle A. T., and Neelapu, Sattva S.

Published
2022
Full Text
View/download PDF

2. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma

Author

Strati, Paolo, Nastoupil, Loretta J., Westin, Jason, Fayad, Luis E., Ahmed, Sairah, Fowler, Nathan H., Hagemeister, Fredrick B., Lee, Hun J., Iyer, Swaminathan P., Nair, Ranjit, Parmar, Simrit, Rodriguez, Maria A., Samaniego, Felipe, Steiner, Raphael E., Wang, Michael, Pinnix, Chelsea C., Adkins, Sherry, Claussen, Catherine M., Martinez, Charles S., Hawkins, Misha C., Johnson, Nicole A., Singh, Prachee, Mistry, Haleigh E., Horowitz, Sandra, George, Shirley, Feng, Lei, Kebriaei, Partow, Shpall, Elizabeth J., Neelapu, Sattva S., Tummala, Sudhakar, and Chi, T. Linda

Published
2020
Full Text
View/download PDF

5. Abstract 4367: The MD Anderson Symptom Inventory (MDASI) survey discloses persistent moderate to high-level symptoms in cancer survivors

Author

Gilmore, Katherine, primary, Chapman, Patricia, additional, Rollins, Johnny, additional, Lee-Kim, Soo-Hyun, additional, Robinson, Justine, additional, Mullen, Ellen, additional, Mistry, Haleigh, additional, Singh, Prachee, additional, Coyne, Robin, additional, Nelson, Ana, additional, Osai, William, additional, Stolar, Karen, additional, Knippel, Susan, additional, Fournier, Danielle, additional, Plair, Tamera, additional, Thoman, Whittney, additional, Peek, Angela, additional, Williams, Loretta, additional, and Rodriguez, Maria A., additional

Published
2023
Full Text
View/download PDF

6. Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response

Author

Jallouk, Andrew P., primary, Gouni, Sushanth, additional, Westin, Jason, additional, Feng, Lei, additional, Mistry, Haleigh, additional, Steiner, Raphael E, additional, James, Jinsu, additional, Noorani, Mansoor, additional, Horowitz, Sandra, additional, Puebla-Osorio, Nahum, additional, Fayad, Luis E, additional, Iyer, Swaminathan P., additional, Hawkins, Misha, additional, Flowers, Christopher R, additional, Ahmed, Sairah, additional, Nastoupil, Loretta J, additional, Kebriaei, Partow, additional, Shpall, Elizabeth J, additional, Neelapu, Sattva S, additional, Nieto, Yago, additional, and Strati, Paolo, additional

Published
2022
Full Text
View/download PDF

7. Comorbidities Associated with Early Mortality after CD19 CAR-T Cell Therapy

Author

Tang, Kevin, primary, Khwaja, Raamis, additional, Feng, Lei, additional, Strati, Paolo, additional, Steiner, Raphael E., additional, Nair, Ranjit, additional, Flowers, Christopher R., additional, Saini, Neeraj, additional, Ramdial, Jeremy L., additional, Srour, Samer A., additional, Champlin, Richard E., additional, Rondon, Gabriela, additional, Torres, Janet, additional, Kebriaei, Partow, additional, Nastoupil, Loretta J., additional, Mistry, Haleigh, additional, Shpall, Elizabeth J., additional, Nieto, Yago, additional, Westin, Jason, additional, Neelapu, Sattva S., additional, and Ahmed, Sairah, additional

Published
2022
Full Text
View/download PDF

8. Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy

Author

Al Zaki, Ajlan, primary, Feng, Lei, additional, Watson, Grace, additional, Ahmed, Sairah A., additional, Mistry, Haleigh, additional, Nastoupil, Loretta J., additional, Hawkins, Misha, additional, Nair, Ranjit, additional, Iyer, Swaminathan P., additional, Lee, Hun J., additional, Steiner, Raphael E., additional, Flowers, Christopher R., additional, Shpall, Elizabeth J., additional, Kebriaei, Partow, additional, Neelapu, Sattva S., additional, Westin, Jason R., additional, and Strati, Paolo, additional

Published
2022
Full Text
View/download PDF

9. Analysis of Factors Associated with Conversion to CR in Patients with Large B-Cell Lymphoma Achieving Day 30 PR after CAR T-Cell Therapy

Author

Al Zaki, Ajlan, primary, Westin, Jason R., additional, Watson, Grace, additional, Feng, Lei, additional, Ahmed, Sairah, additional, Mistry, Haleigh, additional, Nastoupil, Loretta, additional, Hawkins, Misha, additional, Nair, Ranjit, additional, Iyer, Swaminathan P, additional, Lee, Hun, additional, Steiner, Raphael E, additional, Flowers, Christopher R., additional, Shpall, Elizabeth J., additional, Kebriaei, Partow, additional, Neelapu, Sattva S., additional, and Strati, Paolo, additional

Published
2021
Full Text
View/download PDF

10. Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma Patients in Complete Metabolic Response at Time of Infusion

Author

Gouni, Sushanth, primary, Westin, Jason R., additional, Mistry, Haleigh, additional, Steiner, Raphael Eric, additional, James, Jinsu, additional, Parmar, Simrit, additional, Noorani, Mansoor, additional, Fowler, Nathan H., additional, Horowitz, Sandra B., additional, Feng, Lei, additional, Fayad, Luis E., additional, Iyer, Swaminathan P, additional, Green, Michael R, additional, Hawkins, Misha, additional, Flowers, Christopher R., additional, Ahmed, Sairah, additional, Nastoupil, Loretta, additional, Neelapu, Sattva S., additional, Nieto, Yago, additional, and Strati, Paolo, additional

Published
2021
Full Text
View/download PDF

11. Efficacy of Chimeric Antigen Receptor (CAR) T-Cell Therapy, Axicabtagene Ciloleucel (axi-cel), in Patients with Refractory Large B-Cell Lymphoma (LBCL)

Author

Ahmed, Sairah, primary, Strati, Paolo, additional, Fayad, Luis, additional, Hagemeister, Frederick, additional, Lee, Hun Ju, additional, Iyer, Swaminathan P., additional, Nair, Ranjit, additional, Parmar, Simrit, additional, Rodriguez, Alma, additional, Samaniego, Felipe, additional, Steiner, Raphael, additional, Wang, Michael L., additional, Pinnix, Chelsea, additional, Flowers, Christopher, additional, Horowitz, Sandra, additional, Claussen, Catharine, additional, Johnson, Nicole, additional, Mistry, Haleigh, additional, Adkins, Sherry, additional, Shpall, Elizabeth J, additional, Kebriaei, Partow, additional, Nieto, Yago, additional, Hawkins, Misha, additional, Neelapu, Sattva S., additional, Nastoupil, Loretta J., additional, and Westin, Jason R., additional

Published
2021
Full Text
View/download PDF

12. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma

Author

Strati, Paolo, primary, Ahmed, Sairah, additional, Furqan, Fateeha, additional, Fayad, Luis E., additional, Lee, Hun J., additional, Iyer, Swaminathan P., additional, Nair, Ranjit, additional, Nastoupil, Loretta J., additional, Parmar, Simrit, additional, Rodriguez, Maria A., additional, Samaniego, Felipe, additional, Steiner, Raphael E., additional, Wang, Michael, additional, Pinnix, Chelsea C., additional, Horowitz, Sandra B., additional, Feng, Lei, additional, Sun, Ryan, additional, Claussen, Catherine M., additional, Hawkins, Misha C., additional, Johnson, Nicole A., additional, Singh, Prachee, additional, Mistry, Haleigh, additional, Johncy, Swapna, additional, Adkins, Sherry, additional, Kebriaei, Partow, additional, Shpall, Elizabeth J., additional, Green, Michael R., additional, Flowers, Christopher R., additional, Westin, Jason, additional, and Neelapu, Sattva S., additional

Published
2021
Full Text
View/download PDF

13. Prognostic Value of Delta Lymphocyte Index (DLIx) in Patients with Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy

Author

Strati, Paolo, primary, Mistry, Haleigh, additional, Pulsifer, Brittany, additional, Fayad, Luis, additional, Ahmed, Sairah, additional, Lee, Hun Ju, additional, Iyer, Swami P., additional, Nair, Ranjit, additional, Nastoupil, Loretta J., additional, Parmar, Simrit, additional, Rodriguez, Maria Alma, additional, Samaniego, Felipe, additional, Steiner, Raphael Eric, additional, Wang, Michael, additional, Pinnix, Chelsea C., additional, Dabaja, Bouthaina S., additional, Noorani, Mansoor, additional, Claussen, Catherine M., additional, Shpall, Elizabeth J., additional, Kebriaei, Partow, additional, Flowers, Chris R., additional, Westin, Jason R., additional, and Neelapu, Sattva S., additional

Published
2020
Full Text
View/download PDF

15. Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel).

Author

Strati, Paolo, primary, furqan, fateeha, additional, Westin, Jason, additional, Fayad, Luis, additional, Ahmed, Sairah, additional, Lee, Hun Ju, additional, Iyer, Swaminathan Padmanabhan, additional, Nair, Ranjit, additional, Nastoupil, Loretta J., additional, Parmar, Simrit, additional, Rodriguez, Maria Alma, additional, Samaniego, Felipe, additional, Steiner, Raphael, additional, Wang, Michael, additional, Pinnix, Chelsea Camille, additional, Flowers, Christopher, additional, Horowitz, Sandra B., additional, Classen, Catherine, additional, Mistry, Haleigh, additional, and Neelapu, Sattva Swarup, additional

Published
2020
Full Text
View/download PDF

17. Day 30 SUVmaxpredicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy

Author

Al Zaki, Ajlan, Feng, Lei, Watson, Grace, Ahmed, Sairah A., Mistry, Haleigh, Nastoupil, Loretta J., Hawkins, Misha, Nair, Ranjit, Iyer, Swaminathan P., Lee, Hun J., Steiner, Raphael E., Flowers, Christopher R., Shpall, Elizabeth J., Kebriaei, Partow, Neelapu, Sattva S., Westin, Jason R., and Strati, Paolo

Abstract

About 70% of patients with large B-cell lymphoma (LBCL) who are treated with axicabtagene ciloleucel (axi-cel) and who achieve a partial response (PR) or stable disease (SD) on the day 30 (D30) positron emission tomography (PET)–computed tomography (CT) scan progress; however, the factors that are predictive of progression are unknown. This a retrospective study of patients with LBCL who were treated with axi-cel at MD Anderson Cancer Center between January of 2018 and February of 2021. Among 50 patients with D30 PR/SD, 13 (26%) converted to a complete response (CR). Among 95 patients with a D30 CR, 72 (76%) remained in CR. On univariate analysis, the only day −5 characteristic associated with conversion from D30 PR/SD to subsequent CR was a higher platelet count (P= .05). The only D30 factor associated with conversion from D30 PR/SD to subsequent CR was a lower maximum standardized uptake volume (SUVmax; P< .001); all patients with D30 SUVmax≥ 10 progressed. After a median follow-up of 12 months, no significant difference in median progression-free survival was observed between patients who converted from D30 PR/SD to subsequent CR and those who had been in CR since D30 (P= .19). Novel predictive and prognostic markers based on tissue biopsy and noninvasive diagnostic assays are needed to more effectively identify these patients and characterize the biology of their residual disease.

Published
2022
Full Text
View/download PDF

18. 493 - Efficacy of Chimeric Antigen Receptor (CAR) T-Cell Therapy, Axicabtagene Ciloleucel (axi-cel), in Patients with Refractory Large B-Cell Lymphoma (LBCL)

Author

Ahmed, Sairah, Strati, Paolo, Fayad, Luis, Hagemeister, Frederick, Lee, Hun Ju, Iyer, Swaminathan P., Nair, Ranjit, Parmar, Simrit, Rodriguez, Alma, Samaniego, Felipe, Steiner, Raphael, Wang, Michael L., Pinnix, Chelsea, Flowers, Christopher, Horowitz, Sandra, Claussen, Catharine, Johnson, Nicole, Mistry, Haleigh, Adkins, Sherry, Shpall, Elizabeth J, Kebriaei, Partow, Nieto, Yago, Hawkins, Misha, Neelapu, Sattva S., Nastoupil, Loretta J., and Westin, Jason R.

Published
2021
Full Text
View/download PDF

21. Response to pembrolizumab and lenalidomide in advanced refractory mycosis fungoides.

Author

Fountain, Eric, Mistry, Haleigh, Jain, Preetesh, Duvic, Madeleine, and Fowler, Nathan

Subjects
*MYCOSIS fungoides, *CUTANEOUS T-cell lymphoma, *SKIN diseases, *LYMPHOPROLIFERATIVE disorders, *T-cell lymphoma, *PROGRESSION-free survival
Abstract

The article presents a study that determines the effectiveness of immune-mediated therapy in the treatment of mycosis fungoides (MF) and cutaneous T-Cell lymphoma (CTCL). It observes several patients who were diagnosed with MF and CTCL and were given with the treatment intervention. It outlines the result which indicates that the patients have experienced dramatic, durable and ongoing response of the combined pembrolizumab and lenalidomide.

Published
2019
Full Text
View/download PDF

23. Toxicity Management.

Author

Mistry, Haleigh E., Forbes, Sheryl G., and Fowler, Nathan

Subjects
*HODGKIN'S disease treatment, *LYMPHOMA treatment, *ALGORITHMS, *ANTINEOPLASTIC agents, *BIOTHERAPY, *DRUG toxicity, *IMMUNOTHERAPY, *MONOCLONAL antibodies, *QUALITY of life, *HEMATOLOGIC malignancies
Abstract

BACKGROUND: Novel immunotherapyand biologic agents are being developed with the potential to improve outcomes and reduce long-term toxicities among individuals with hematologic malignancies. These emerging drugs affect neoplastic cells and the surrounding microenvironment, causing unique immune-mediated toxicities. OBJECTIVES: The aim was to develop an algorithm for clinical staff to manage unique toxicities associated with next-generation immunotherapies indicated in the hematologic population, using a system-focused approach. METHODS: Data were collected using specific toxicities based on the four major novel biologic classes. Immune-mediated adverse events were reported across studies. Based on published literature, institutional experience, and group consensus, a novel algorithm for managing immune-mediated toxicities was created. FINDINGS: The development of this treatment algorithm provides a more streamlined approach for managing common but unique toxicities and improves safety, compliance, patient outcome, and quality of life with novel immuno-oncologic agents. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

26. Integration of patient-reported outcomes into survivorship care.

Author

Gilmore, Katherine Ramsey, Chapman, Patricia Hansberry, Rollins, Johnny, Lee-Kim, Soo, Robinson, Justine, Mullen, Ellen, Mistry, Haleigh, Singh, Prachee, Coyne, Robin, Nelson, Ana, Osai, William, Stolar, Karen, Knippel, Susan, Fournier, Danielle M., Plair, Tamera, Peek, Angela, and Rodriguez, Maria Alma

Published
2022
Full Text
View/download PDF

27. Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response.

Author

Jallouk AP, Gouni S, Westin J, Feng L, Mistry H, Steiner RE, James J, Noorani M, Horowitz S, Puebla-Osorio N, Fayad LE, Iyer SP, Hawkins M, Flowers CR, Ahmed S, Nastoupil LJ, Kebriaei P, Shpall EJ, Neelapu SS, Nieto Y, and Strati P

Subjects
Humans, Immunotherapy, Adoptive, Antigens, CD19, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Large B-Cell, Diffuse pathology, Biological Products therapeutic use
Published
2023
Full Text
View/download PDF

28. Biomarker Jeopardy.

Author

Kurtin SE, Henglefelt A, and Mistry H

Abstract

In the popular Biomarker Jeopardy session, Sandra E. Kurtin, PhD, ANP-C, AOCN®, Alyssa Henglefelt, PharmD, BCOP, and Haleigh Mistry, MS, PA-C, paired biomarkers with tumor types for which their expression is most commonly used to determine targeted therapy, identified key assays used to measure common biomarkers, and discussed guidelines for biomarker testing., Competing Interests: Dr. Kurtin has served as a consultant for AbbVie, Amgen, BMS, Celgene, GSK, and Incyte. Ms. Mistry reported financial relationships with ADC Therapeutics, Bayer, Astrazeneca, and Genentech/Roche. Dr. Henglefelt had no conflicts of interest to disclose., (© 2022 Harborside™.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results